Here is what you need to know on Friday, December 17:
Equity markets retreated on Thursday as renewed fears over Omicron hit sentiment and Build Back Better looks unlikely to pass this year if at all. Infrastructure and green stocks were disproportionally knocked down a peg, and Tesla (TSLA) nearly reached our $910 target. President Biden and Senator Manchin are reportedly still miles away from reaching an agreement on the plan. This will hit stocks further in the new year if not sorted soon.
The Nasdaq was the big loser, index wise, on Thursday, as rate hike probabilities fed through to institutional investor positioning. Yield sensitive, unprofitable names will likely struggle, but so-called new defensives also struggled. The poster child for this new breed of cash-rich, defensive stocks, Apple (AAPL) fell 4% on Thursday.
The dollar, meanwhile, has reset and is stronger this morning at 1.1310 versus the euro. Bitcoin is $47,100, and oil is at $71.19, despite Goldman forecasting record demand for 2022 and 2023.
See Forex Today.
European markets are lower: Eurostoxx -0.85, FTSE +0.2% and Dax -15.
US futures are lower: S&P -0.6%, Dow -0.45 and Nasdaq -1%.
Wall Street (SPY) (QQQ) news
Record high for UK covid cases on Thursday.
Rivian (RIVN): Q3 earnings and production shortfall see stock fall 9%.
Tesla (TSLA): Elon sells more stock.
Apple (AAPL) slides 4% on Thursday.
FedEx (FDX) up 5% on reinstating 2022 forecasts.
Darden Restaurants (DRI) earnings beat on the top and bottom lines. CEO to retire in May.
Freshpet (FRPT) down 11% on lower guidance.
Johnson & Johnson (JNJ), Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX): US FDA recommends booster shots use only Moderna or Pfizer. JNJ down 2% premarket.
Novavax (NVAX): WHO issues emergency use listing.
US Steel (X) issues lower guidance than forecast, falls 4%.
Affirm (AFRM) down 2% as US launches probe into Buy Now Pay Later credit.
Cerner (CERN) up 18% on WSJ article that Oracle (ORCL) is in talks to buy it.
Upgrades and downgrades
Source: Benzinga Pro
Economic releases
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD edges lower toward 1.0700 post-US PCE
EUR/USD stays under modest bearish pressure but manages to hold above 1.0700 in the American session on Friday. The US Dollar (USD) gathers strength against its rivals after the stronger-than-forecast PCE inflation data, not allowing the pair to gain traction.
GBP/USD retreats to 1.2500 on renewed USD strength
GBP/USD lost its traction and turned negative on the day near 1.2500. Following the stronger-than-expected PCE inflation readings from the US, the USD stays resilient and makes it difficult for the pair to gather recovery momentum.
Gold struggles to hold above $2,350 following US inflation
Gold turned south and declined toward $2,340, erasing a large portion of its daily gains, as the USD benefited from PCE inflation data. The benchmark 10-year US yield, however, stays in negative territory and helps XAU/USD limit its losses.
Bitcoin Weekly Forecast: BTC’s next breakout could propel it to $80,000 Premium
Bitcoin’s recent price consolidation could be nearing its end as technical indicators and on-chain metrics suggest a potential upward breakout. However, this move would not be straightforward and could punish impatient investors.
Week ahead – Hawkish risk as Fed and NFP on tap, Eurozone data eyed too
Fed meets on Wednesday as US inflation stays elevated. Will Friday’s jobs report bring relief or more angst for the markets? Eurozone flash GDP and CPI numbers in focus for the Euro.